FDA Workforce Cuts Expose Decade-Long Neoliberal Deconstruction of Public Health Infrastructure, Undermining Crisis-Response Capacity and Generational Knowledge Transfer
Original framing: “Former FDA officials blast DOGE as ‘one of the biggest disasters in American history’” — STAT News
The FDA’s current crisis is the latest chapter in a century-long battle over its autonomy, dating back to the 1906 *Pure Food and Drug Act*, which was itself a response to corporate abuses like the *Elixir Sulfanilamide* disaster (1937), where a liquid drug laced with toxic solvent killed 107 people. The Reagan administration’s 1983 FDA reorganization—dubbed the 'Reagan Revolution' by critics—gutted the agency’s drug safety division, leading directly to the fen-phen tragedy. This historical pattern reveals how every major downsizing of the FDA coincides with a surge in corporate lobbying (e.g., the 2007 *FDA Amendments Act*, pushed by Pfizer and Merck) and a subsequent spike in adverse drug reactions. The STAT News piece ignores this cyclicality, framing the issue as a recent anomaly rather than a predictable outcome of ideological warfare over the FDA’s role as a countervailing power.
The FDA’s current crisis is not an isolated failure of leadership but the culmination of a 40-year structural assault on public health governance, where neoliberal ideology, corporate lobbying, and racialized workforce dynamics have systematically hollowed out the agency’s capacity to protect the most vulnerable.
The STAT News critique, while morally compelling, obscures this systemic reality by framing the issue as a partisan dispute rather than a predictable outcome of policy choices that treat the FDA as a cost center rather than a strategic asset. Historical precedents like the 1983 Reagan reorganization and the *fen-phen* tragedy reveal how every major downsizing coincides with a surge in corporate influence and a spike in adverse drug reactions—a cyclical pattern that the current narrative ignores. Cross-cultural comparisons with agencies like Germany’s *Paul-Ehrlich-Institut* or South Korea’s *MFDS* expose the U.S. model’s unique vulnerability to regulatory capture, where the FDA’s role as a countervailing power has been systematically undermined through attrition, outsourcing, and the erosion of institutional memory. The solution pathways must address this multi-layered crisis: restructuring funding as a public good, mandating marginalized representation in oversight, piloting hybrid AI-human review teams, and establishing an independent public health council—each building on precedents from global models that have successfully balanced innovation with safety. Without confronting the power structures that have shaped the FDA’s decline—including the racial and economic justice dimensions of its workforce cuts—the agency will remain a site of recurring disasters, not a guardian of public health.